SAT0462 Secukinumab provides sustained pasdas related low disease activity in psoriatic arthritis: 2 year results from the future 2 study

@article{Coates2017SAT0462SP,
  title={SAT0462 Secukinumab provides sustained pasdas related low disease activity in psoriatic arthritis: 2 year results from the future 2 study},
  author={Laura C Coates and Dafna D Gladman and Peter Nash and Oliver Fitzgerald and Arthur Scott Kavanaugh and Lawrence Rasouliyan and L. Pricorp and Kevin Ding and Corine Gaillez},
  journal={Annals of the Rheumatic Diseases},
  year={2017},
  volume={76},
  pages={948–949}
}
Background Psoriatic arthritis (PsA) disease activity score (PASDAS) assessing multiple facets of PsA was demonstrated to distinguish treatment effect, perform better in statistical terms than traditional joint-only indices1 and could be used as a treatment target in clinical trials in PsA. Objectives Secukinumab provided sustained improvement in the signs and symptoms of PsA over 104 weeks (wks) in the FUTURE 2 study.2 Here, we report the ability of secukinumab to reach and sustain PASDAS… CONTINUE READING